| Title: |
Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task |
| Authors: |
Tommaso Cassano, Silvio Calcagnini, Antonio Carbone, Vidyasagar Naik Bukke, Stanislaw Orkisz, Rosanna Villani, Adele Romano, Carlo Avolio, Silvana Gaetani |
| Source: |
Frontiers in Pharmacology, Vol 10 (2019) |
| Publisher Information: |
Frontiers Media S.A., 2019. |
| Publication Year: |
2019 |
| Collection: |
LCC:Therapeutics. Pharmacology |
| Subject Terms: |
Alzheimer’s disease, depression, amyloid-β peptide, tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin, Therapeutics. Pharmacology, RM1-950 |
| More Details: |
Besides the memory impairment, Alzheimer’s disease (AD) is often complicated by neuropsychiatric symptoms also known as behavioral and psychological symptoms of dementia, which occur in one-third of patients at an early stage of the disease. Although the relationship between depressive disorders and AD is debated, the question if depression is a prodromal symptom preceding cognitive deficits or an independent risk factor for AD is still unclear. Moreover, there is growing evidence reporting that conventional antidepressants are not effective in depression associated with AD and, therefore, there is an urgent need to understand the neurobiological mechanism underlying the resistance to the antidepressants. Another important question that remains to be addressed is whether the antidepressant treatment is able to modulate the levels of amyloid-β peptide (Aβ), which is a key pathological hallmark in AD. The present review summarizes the present knowledge on the link between depression and AD with a focus on the resistance of antidepressant therapies in AD patients. Finally, we have briefly outlined the preclinical and clinical evidences behind the possible mechanisms by which antidepressants modulate Aβ pathology. To our opinion, understanding the cellular processes that regulate Aβ levels may provide greater insight into the disease pathogenesis and might be helpful in designing novel selective and effective therapy against depression in AD. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1663-9812 |
| Relation: |
https://www.frontiersin.org/article/10.3389/fphar.2019.01067/full; https://doaj.org/toc/1663-9812 |
| DOI: |
10.3389/fphar.2019.01067 |
| Access URL: |
https://doaj.org/article/55e7e3d9e6494b68853c5e3606bb49c5 |
| Accession Number: |
edsdoj.55e7e3d9e6494b68853c5e3606bb49c5 |
| Database: |
Directory of Open Access Journals |
